[1] FU J,WU H.Structural mechanisms of NLRP3 inflammasome assembly and activation[J].Annu Rev Immunol,2023,41:301-316.

[2] WU B,LUO Y,WU D,et al.Phenotypic and genotypic characterization of Chinese adult patients with NLRP3-associated autoinflammatory disease with hearing loss[J].Rheumatology (Oxford),2023.DOI:10.1093/rheumatology/kead451.

[3] OZIEBLO D,LEJA M L,JEZNACH A,et al.Hearing loss as the main clinical presentation in NLRP3-associated autoinflammatory disease[J].Front Immunol,2022,13:904632.

[4] WU L,CHEN M,LI M,et al.Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis[J].Mol Immunol,2022,149:66-76.

[5] BURDETTE B E,ESPARZA A N,ZHU H,et al.Gasdermin D in pyroptosis[J].Acta pharmaceutica Sinica B,2021,11(9):2768-2782.

[6] CHEN C,XU P.Activation and pharmacological regulation of inflammasomes[J].Biomolecules,2022,12(7).DOI:10.3390/biom12071005.

[7] ZHAN X,LI Q,XU G,et al.The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors[J].Front Immunol,2022,13:1109938.

[8] HUANG Y,XU W,ZHOU R.NLRP3 inflammasome activation and cell death[J].Cellular & Molecular Immunology,2021,18(9):2114-2127.

[9] LI P,LI S,WANG L,et al.Mitochondrial dysfunction in hearing loss:oxidative stress,autophagy and NLRP3 inflammasome[J].Front Cell Dev Biol,2023,11:1119773.

[10] WRIGHT S S,VASUDEVAN S O,RATHINAM V A.Mechanisms and consequences of noncanonical inflammasome-mediated pyroptosis[J].J Mol Biol,2022,434(4):167245.

[11] KEITHLEY E M.Inner ear immunity[J].Hear Res,2022,419:108518.

[12] ITO T,KURATA N,FUKUNAGA Y.Tissue-resident macrophages in the stria vascularis[J].Front Neurol,2022,13:818395.

[13] NAKANISHI H,OKANO T,ITO T,et al.Editorial:autoinflammation of the inner ear[J].Front Neurol,2022,13:1071382.

[14] WELZEL T,KUEMMERLE-DESCHNER J B.Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS):what do we know today?[J].J Clin Med,2021,10(1).

[15] MURAKAWA S,YONEDA T,HOSHINA T,et al.Case report:the altered rate of monocytic cell death in a patient of Muckle-Wells syndrome with atypical clinical course[J].Front Pediatr,2023,11:1133097.

[16] MA J H,LEE E,YOON S H,et al.Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model[J].EBio Medicine,2022,82:104184.

[17] YUAN Z,YU D,GOU T,et al.Research progress of NLRP3 inflammasome and its inhibitors with aging diseases[J].Eur J Pharmacol,2023,957:175931.

[18] MODI P,SHAH B M,PATEL S.Interleukin-1β converting enzyme (ICE):a comprehensive review on discovery and development of caspase-1 inhibitors[J].European Journal of Medicinal Chemistry,2023,261:115861.

[19] ARNOLD D D,YALAMANOGLU A,BOYMAN O.Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders[J].Front Immunol,2022,13:888392.

[20] NAKANISHI H,YAMADA S,KITA J,et al.Auditory and vestibular characteristics of NLRP3 inflammasome related autoinflammatory disorders:monogenic hearing loss can be improved by anti-interleukin-1 therapy[J].Front Neurol,2022,13:865763.

[21] KIM B J,KIM Y H,LEE S,et al.Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra[J].Rheumatology (Oxford),2021,60(3):1523-1532.

[22] YU R,WANG K,LUO W,et al.Knockdown and mutation of Pou4f3 gene mutation promotes pyroptosis of cochleae in cisplatin-induced deafness mice by NLRP3/caspase-3/GSDME pathway[J].Toxicology,2022,482:153368.

[23] WANG X,ZHOU Y,WANG D,et al.Cisplatin-induced ototoxicity:from signaling network to therapeutic targets[J].Biomed Pharmacother,2023,157:114045.

[24] YU W,ZONG S,ZHOU P,et al.Cochlear marginal cell pyroptosis is induced by cisplatin via NLRP3 inflammasome activation[J].Front Immunol,2022,13:823439.

[25] NOBLE K,BROWN L,ELVIS P,et al.Cochlear immune response in presbyacusis:a focus on dysregulation of macrophage activity[J].J Assoc Res Otolaryngol,2022,23(1):1-16.

[26] YANG X,WU Y,ZHANG M,et al.Piceatannol protects against age-related hearing loss by inhibiting cellular pyroptosis and inflammation through regulated Caspase11-GSDMD pathway[J].Biomed Pharmacother,2023,163:114704.

[27] SAI N,YANG Y Y,MA L,et al.Involvement of NLRP3-inflammasome pathway in noise-induced hearing loss[J].Neural Regen Res,2022,17(12):2750-2754.

[28] CHEN M B,LI M H,WU L Y,et al.Oridonin employs interleukin 1 receptor type 2 to treat noise-induced hearing loss by blocking inner ear inflammation[J].Biochem Pharmacol,2023,210:115457.

[29] LI M,ZHANG Y,QIU S,et al.Oridonin ameliorates noise-induced hearing loss by blocking NLRP3-NEK7 mediated inflammasome activation[J].Int Immunopharmacol,2021,95:107576.

[30] PACIELLO F,PISANI A,ROLESI R,et al.Noise-induced cochlear damage involves PPAR down-regulation through the interplay between oxidative stress and inflammation[J].Antioxidants (Basel,Switzerland),2021,10(8).DOI:10.3390/antiox10081188.

[31] ZHANG D G,YU W Q,LIU J H,et al.Serum/glucocorticoid-inducible kinase 1 deficiency induces NLRP3 inflammasome activation and autoinflammation of macrophages in a murine endolymphatic hydrops model[J].Nat Commun,2023,14(1):1249.

[32] BROWN A,EARLY S,VASILIJIC S,et al.Sporadic vestibular schwannoma size and location do not correlate with the severity of hearing loss at initial presentation[J].Frontiers in Oncology,2022,12:836504.

[33] LEE S A,KIM S Y,LEE Y,et al.Efficacy of steroid treatment for sudden sensorineural hearing loss in patients with vestibular schwannoma[J].Acta Oto-laryngologica,2022,142(5):402-405.

[34] NISENBAUM E,MISZTAL C,SZCZUPAK M,et al.Tumor-associated macrophages in vestibular schwannoma and relationship to hearing[J].OTO Open,2021,5(4):2473974x211059111.

[35] WU L,VASILIJIC S,SUN Y,et al.Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models[J].Science Translational Medicine,2021,13(602).DOI:10.1126/scitranslmed.nbd4816.

[36] SAGERS J E,SAHIN M I,MOON I,et al.NLRP3 inflammasome activation in human vestibular schwannoma:implications for tumor-induced hearing loss[J].Hear Res,2019,381:107770.

[37] BOMMAKANTI K,SEIST R,KUKUTLA P,et al.Comparative transcriptomic analysis of archival human vestibular schwannoma tissue from patients with and without Tinnitus[J].J Clin Med,2023,12(7).DOI:10.3390/jcm12072642.

[38] LI S,HUANG H,WEI Q,et al.Depression of pyroptosis by inhibiting Caspase-1 activation improves neurological outcomes of kernicterus model rats[J].ACS Chem Neurosci,2021,12(15):2929-2939.

[39] SUN S,YU S,YU H,et al.The pyroptosis mechanism of ototoxicity caused by unconjugated bilirubin in neonatal hyperbilirubinemia[J].Biomed Pharmacother,2023,165:115162.

[40] WANG J,DING Q,YANG Q,et al.Vibrio alginolyticus triggers inflammatory response in mouse peritoneal macrophages via activation of NLRP3 inflammasome[J].Frontiers in Cellular and Infection Microbiology,2021,11:769777.

[41] ENOSI TUIPULOTU D,FENG S,PANDEY A,et al.Immunity against moraxella catarrhalis requires guanylate-binding proteins and caspase-11-NLRP3 inflammasomes[J].The EMBO Journal,2023,42(6):e112558.

[42] WANG X,ZHAO Y,WANG D,et al.ALK-JNK signaling promotes NLRP3 inflammasome activation and pyroptosis via NEK7 during Streptococcus pneumoniae infection[J].Mol Immunol,2023,157:78-90.

[43] YOU M W,KIM D,LEE E H,et al.The roles of NOD-like receptors in innate immunity in otitis media[J].Int J Mol Sci,2022,23(4).DOI:10.3390/ijm323042350.

[44] LIN S,ZHANG W,XU Y,et al.Gene expression analysis reveals immune and metabolic candidate pathways in the pathogenesis of chronic otitis media[J].Am J Transl Res,2022,14(1):264-274.